|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted Cash | ||||||||||||||||||||
| Clinical trial services asset | ||||||||||||||||||||
| Trade receivables, net of credit losses of $212 and $192, as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| LONG-TERM ASSETS | ||||||||||||||||||||
| Restricted cash and other long-term assets | ||||||||||||||||||||
| Clinical trial services asset | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Intangible Assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total long-term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Trade payables | ||||||||||||||||||||
| Employees and payroll accruals | ||||||||||||||||||||
| Deferred revenues | ||||||||||||||||||||
| Convertible promissory note | ||||||||||||||||||||
| Current maturities of operating leases liability | ||||||||||||||||||||
| Earnout liability | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| LONG-TERM LIABILITIES | ||||||||||||||||||||
| Earnout liability | ||||||||||||||||||||
| Convertible promissory notes, net | ||||||||||||||||||||
| Financing liabilities | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Deferred revenues | ||||||||||||||||||||
| Non-current operating leases liability | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Share capital Ordinary share Authorized: 100,000,000 shares at June 30, 2026 and 75,000,000 December 31, 2025; Issued: 2,876,250 and 1,572,319 shares at June 30, 2026 and December 31, 2025, respectively; Outstanding: 2,828,362 and 1,524,431 shares as of June 30, 2026 and December 31, 2025 respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury Shares at cost, 47,888 ordinary shares at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity |
Loading...
